AstraZeneca (AZN) Stock Rating Lowered by ValuEngine
AstraZeneca (NYSE:AZN) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
A number of other brokerages have also recently weighed in on AZN. BMO Capital Markets reaffirmed a “buy” rating and issued a $41.00 price objective on shares of AstraZeneca in a research note on Friday, May 25th. Zacks Investment Research cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, June 29th. Morningstar reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Tuesday, June 12th. Finally, Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. AstraZeneca presently has an average rating of “Hold” and an average target price of $38.94.
Shares of NYSE AZN opened at $37.18 on Friday. AstraZeneca has a twelve month low of $31.71 and a twelve month high of $39.76. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $93.89 billion, a PE ratio of 8.69, a PEG ratio of 2.00 and a beta of 0.60.
A number of large investors have recently added to or reduced their stakes in AZN. Bessemer Group Inc. boosted its holdings in AstraZeneca by 64.3% in the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after purchasing an additional 1,820 shares during the period. FNY Investment Advisers LLC purchased a new position in AstraZeneca in the second quarter valued at $175,000. Tiverton Asset Management LLC purchased a new position in AstraZeneca in the second quarter valued at $178,000. Gilman Hill Asset Management LLC purchased a new position in AstraZeneca in the second quarter valued at $205,000. Finally, Independent Advisor Alliance purchased a new position in AstraZeneca in the second quarter valued at $206,000. Hedge funds and other institutional investors own 15.98% of the company’s stock.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.